Scarica l'app Stockscreener
9.91
0.70%
-0.07
Dopo l'orario di chiusura:
9.76
-0.15
-1.51%
Precedente Chiudi:
$9.98
Aprire:
$10.04
Volume 24 ore:
170.96K
Relative Volume:
0.51
Capitalizzazione di mercato:
$198.13M
Reddito:
-
Utile/perdita netta:
$-52.07M
Rapporto P/E:
-47.71
EPS:
-0.2077
Flusso di cassa netto:
$-44.93M
1 W Prestazione:
-1.20%
1M Prestazione:
+12.36%
6M Prestazione:
-6.76%
1 anno Prestazione:
-31.37%
Intervallo 1D:
$9.78
$10.23
Intervallo di 1 settimana:
$9.3501
$10.23
Portata 52W:
$6.50
$19.85
Cybin Inc Stock (CYBN) Company Profile
Nome
Cybin Inc
Settore
Industria
Telefono
908 764 8385
Indirizzo
100 King Street West, Suite 5600, Toronto
Confronta CYBN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
9.91 | 198.13M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-11-19 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Borsa (CYBN) Ultime notizie
What is HC Wainwright's Forecast for Cybin FY2029 Earnings? - MarketBeat
How To Trade (CYBN) - Stock Traders Daily
HC Wainwright Comments on Cybin's Q3 Earnings (NYSE:CYBN) - MarketBeat
Equities Analysts Issue Forecasts for Cybin FY2029 Earnings - MarketBeat
Cybin (OTCMKTS:CLXPF) Trading Up 1.9%Here's What Happened - MarketBeat
Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade - Yahoo Finance
H.C. Wainwright maintains $190 target on Cybin Inc. shares - Investing.com
H.C. Wainwright maintains $190 target on Cybin Inc. shares By Investing.com - Investing.com Canada
HC Wainwright Reiterates "Buy" Rating for Cybin (NYSE:CYBN) - MarketBeat
Cybin (OTCMKTS:CYBN) Shares Up 1.8%Should You Buy? - MarketBeat
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
(CYBN) Trading Signals - Stock Traders Daily
Cybin Inc: Paradigm Changing Ambitions (NYSE:CYBN) - Seeking Alpha
Cybin enters partnership agreement to conduct phase 3 trial for depression candidate - MSN
Cybin Partners with Segal Trials for Pivotal Phase 3 Program - TipRanks
Cybin launches phase 3 trial for depression treatment - Investing.com India
Cybin launches clinical site partnerships to support PARADIGM program - TipRanks
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
Thinking about buying stock in Hanryu Holdings, Absci Corp, Spero Therapeutics, BioXcel Therapeutics, or Cybin? - Marketscreener.com
Occidental Petroleum Corp (OXY-N) QuotePress Release - The Globe and Mail
Cybin Inc. Achieves Breakthroughs in Mental Health Treatment - TipRanks
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 - Financial Post
Jane Street Group LLC Has $204,000 Stake in Cybin Inc. (NYSE:CYBN) - Defense World
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - BioSpace
Cybin CEO to Present at Lytham Partners Healthcare Summit: Mental Health Innovation Spotlight - StockTitan
Cybin (OTCMKTS:CLXPF) Trading 5.4% Higher – Time to Buy? - Defense World
BUSINESS WIRE NEWS RELEASES - Wallaceburg Courier Press
Cybin (OTCMKTS:CYBN) Trading Down 2% – Here’s What Happened - Defense World
Learn to Evaluate (CYBN) using the Charts - Stock Traders Daily
Cybin (NYSE:CYBN) Stock Price Up 1%Here's Why - MarketBeat
Objective long/short (CYBN) Report - Stock Traders Daily
Cybin (FRA:R7E) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
Facet Life Sciences Partners with Cybin to Advance Mental Health Therapies - MSN
Cybin Reveals Promising Results in Depression Treatment - TipRanks
Cybin's Breakthrough Clinical Data Shows 100% Response Rate in Depression Treatment Study - StockTitan
(CYBN) Investment Report - Stock Traders Daily
PEAK6 Investments LLC Sells 420,512 Shares of Cybin Inc. (NYSE:CYBN) - MarketBeat
Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish - MSN
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 - Chatham-Kent This Week
Cybin to Discuss Breakthrough Treatments at Fireside Chat - TipRanks
TANG CAPITAL MANAGEMENT LLC Increases Stake in Cybin Inc - GuruFocus.com
Psychedelic Drugs Market Growth in Future Scope 2024-2031 | - openPR
Cybin (FRA:R7E) 3-Year EPS without NRI Growth Rate : 6.10% (As of Sep. 2024) - GuruFocus.com
Cybin (FRA:R7E) 50-Day SMA : €9.05 (As of Nov. 30, 2024) - GuruFocus.com
Cybin (OTCMKTS:CYBN) Stock Price Down 4.3%What's Next? - MarketBeat
FDA's Psychedelic Reckoning - Life Science Leader Magazine
Cybin (STU:R7E) Earnings Yield (Joel Greenblatt) % : -151.52% (As of Sep. 2024) - GuruFocus.com
Cybin Inc. Advances in Mental Health Treatments - TipRanks
Cybin (STU:R7E) Change In Receivables : €-1.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
What is Bloom Burton's Estimate for Cybin FY2025 Earnings? - MarketBeat
Cybin Inc Azioni (CYBN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Capitalizzazione:
|
Volume (24 ore):